Publications
2021
| 92. | Düsterhöft S, Kahveci-Türköz S, Wozniak J, Seifert A, Kasparek P, Ohm H, Liu S, Kopkanova J, Lokau J, Garbers C, Preisinger C, Sedlacek R, Freeman M, Ludwig A (2021) The iRhom homology domain is responsible for ADAM17-mediated TNFα and EGF receptor ligand release. Cell Mol Life Sci [in press] |
| 91. | Kespohl B,Schumertl T, Bertrand J, Lokau J, Garbers C (2021) The cytokine interleukin-11 crucially links bone formation, remodeling and resorption. Cytokine Growth Factor Rev [in press] |
| 90. | |
| 89. | Schreiber S, Aden K, Bernardes JP, Conrad C, Tran F, Höper H, Volk V, Mishra N, Blase JI, Nikolaus S, Bethge J, Kühbacher T, Röcken C, Chen M, Cottingham I, Petri N, Rasmussen BB, Lokau J, Lenk L, Garbers C, Feuerhake F, Rose-John S, Waetzig GH, Rosenstiel P (2021) Therapeutic IL-6 trans-signalling inhibition by olamkicept (sgp130Fc) in patients with active inflammatory bowel disease. Gastroenterology [in press] |
| 88. | Flynn CM, Kespohl B, Daunke T, Garbers Y, Düsterhöft S, Rose-John S, Haybaeck J, Lokau J, Aparicio-Siegmund S, Garbers C (2021) Interleukin-6 controls recycling and degradation, but not internalization of its receptors. J Biol Chem 18:100434 |
| 87. | Koch L, Kespohl B, Agthe M, Schumertl T, Düsterhöft S, Lemberg MK, Lokau J, Garbers C (2021) Interleukin-11 (IL-11) receptor cleavage by the rhomboid protease RHBDL2 induces IL-11 trans-signaling. FASEB J 35(3):e21380 |
| 86. | Westermann LM, Baranowsky A, Di Lorenzo G, Danyukova T, Soul J, Schwartz JM, Hendrickx G, Amling M, Rose-John S, Garbers C, Schinke T, Pohl S (2021) Transgenic inhibition of interleukin-6 trans-signaling does not prevent skeletal pathologies in mucolipidosis type II mice. Sci Rep 11(1):3556 |
| 85. | Garbers C, Rose-John S (2021) Genetic IL-6R variants and therapeutic inhibition of IL-6 receptor signalling in COVID-19. Lancet Rheumatol 3(2):e96-e97 |
2020
| 84. | Flynn CM, Garbers Y, Düsterhöft S, Wichert R, Lokau J, Lehmann CHK, Dudziak D, Schröder B, Becker-Pauly C, Rose-John S, Aparicio-Siegmund S, Garbers C (2020) Cathepsin S provokes interleukin-6 (IL-6) trans-signaling through cleavage of the IL-6 receptor in vitro. Sci Rep 10(1):21612 |
| 83. | Lokau J, Waetzig GH, Rose-John S, Garbers C (2020) Non-specific effects resulting from use of tocilizumab in mice. Metabolism 28:154281 |
| 82. | Lokau J, Garbers C (2020) Biological functions and therapeutic opportunities of soluble cytokine receptors. Cytokine Growth Factor Rev 55:94-108 |
| 81. | Arnold P, Lückstädt W, Li W, Boll I, Lokau J, Garbers C, Lucius R, Rose-John S, Becker-Pauly C (2020) Joint Reconstituted Signaling of the IL-6 Receptor via Extracellular Vesicles. Cells 9(5):1307 |
| 80. | Lokau J, Kleinegger F, Garbers Y, Waetzig GH, Grötzinger J, Rose-John S, Haybaeck J, Garbers C (2020) Tocilizumab does not block interleukin-6 (IL-6) signaling in murine cells. PLOS One 15(5):e0232612 |
| 79. | Garbers C, Rose-John S (2020) Soluble interleukin-6 receptor in patients with JAK2V617F somatic mutation and myeloproliferative neoplasm. EClinicalMedicine 3;22:100340 |
| 78. | Düsterhöft S, Bartels AK, Koudelka T, Lilienthal E, Schäfer M, Garbers C, Tholey A, Grötzinger J, Lorenzen I (2020) Distance dependent shedding of IL-6R. Biochem Biophys Res Commun 526(2):355-360 |
| 77. | Lokau J, Schoeder V, Garbers C (2020) [The role of interleukin-11 in osteosarcoma]. Pathologe 41(2):163-167 |
2019
| 76. | Martinez-Fabregas J, Wilmes S, Wang L, Hafer M, Pohler E, Lokau J, Garbers C, Cozzani A, Piehler J, Kazemian M, Mitra S, Moraga I (2019) Kinetics of cytokine receptor trafficking determine signaling and functional selectivity. eLife pii: e49314 |
| 75. | Lokau J, Schoeder V, Haybaeck J, Garbers C (2019) Jak-STAT signaling induced by interleukin-6 family cytokines in hepatocellular carcinoma. Cancers (Basel) 11(11). pii: E1704 |
| 74. | Findeisen M, Allen TL, Henstridge DC, Kammoun H, Brandon AE, Baggio LL, Watt KI, Pal M, Cron L, Estevez E, Yang C, Kowalski GM, O’Reilly L, Egan C, Sun E, Thai LM, Krippner G, Adams TE, Lee RS, Grötzinger J, Garbers C, Risis S, Kraakman MJ, Mellet NA, Sligar J, Kimber ET, Young RL, Cowley MA Bruce CR, Meikle PJ, Baldock PA, Gregorevic P, Biden TJ, Cooney GJ, Keating DJ, Drucker DJ, Rose-John S, Febbraio MA (2019) Treatment of type 2 diabetes with the designer cytokine IC7Fc. Nature 574(7776):63-68 |
| 73. | Dos Santos Guilherme M, Stoye NM, Rose-John S, Garbers C, Fellgiebel A, Endres K (2019) The Synthetic Retinoid Acitretin Increases IL-6 in the Central Nervous System of Alzheimer Disease Model Mice and Human Patients. Front Aging Neurosci 11:182 |
| 72. | Sammel M, Peters F, Lokau J, Scharfenberg F, Werny L, Linder S, Garbers C, Rose-John S, Becker-Pauly C (2019) Differences in Shedding of the Interleukin-11 Receptor by the Proteases ADAM9, ADAM10, ADAM17, Meprin α, Meprin β and MT1-MMP. Int J Mol Sci 20(15). pii: E3677 |
| 71. | Aparicio-Siegmund S, Garbers Y, Flynn CM, Waetzig GH, Gouni-Berthold I, Krone W, Berthold HK, Laudes M, Rose-John S, Garbers C (2019) The IL-6-neutralizing sIL-6R-sgp130 buffer system is disturbed in patients with type 2 diabetes. Am J Physiol Endocrinol Metab 317(2):E411-E420 |
| 70. | Flynn CM, Garbers Y, Lokau J, Wesch D, Schulte DM, Laudes M, Lieb W, Aparicio-Siegmund A, Garbers C (2019) Activation of Toll-like Receptor 2 (TLR2) induces Interleukin-6 trans-signaling. Sci Rep 9(1):7306 |
| 69. | Düsterhöft S, Lokau J, Garbers C (2019) The metalloprotease ADAM17 in inflammation and cancer. Pathol Res Pract 215(6):152410 |
| 68. | Saad MI, Alhayyani S, McLeod L, Yu L, Alanazi M, Deswaerte V, Tang K, Jarde T, Smith JA, Prodanovic Z, Tate MD, Balic JJ, Watkins DN, Cain JE, Bozinovski S, Algar E, Kohmoto T, Ebi H, Ferlin W, Garbers C, Ruwanpura S, Sagi I, Rose-John S, Jenkins BJ (2019) ADAM17 selectively activates the IL-6 trans-signaling/ERK MAPK axis in KRAS-addicted lung cancer. EMBO Mol Med e9976 |
| 67. | Prenissl N, Lokau J, Rose-John S, Haybaeck J, Garbers C (2019) Therapeutic blockade of the interleukin-6 receptor (IL-6R) allows sIL-6R generation by proteolytic cleavage. Cytokine 114: 1-5 |
| 66. | Kleinegger F, Hofer E, Wodlej C, Golob-Schwarzl N, Birkl-Toeglhofer AM, Stallinger A, Petzold J, Orlova A, Krassnig S, Reihs R, Niedrist T, Mangge H, Park YN, Thalhammer M, Aigelsreiter A, Lax S, Garbers C, Fickert P, Rose-John S, Moriggl R, Rinner B, Haybaeck J (2019) Pharmacologic IL-6Rα inhibition in cholangiocarcinoma promotes cancer cell growth and survival. Biochim Biophys Acta Mol Basis Dis 1865(2): 308-321 |
2018
| 65. | Agthe M, Brügge J, Garbers Y, Wandel M, Kespohl B, Arnold P, Flynn CM, Lokau J, Aparicio-Siegmund S, Bretscher C, Rose-John S, Waetzig GH, Putoczki T, Grötzinger J, Garbers C (2018) Mutations in Craniosynostosis Patients Cause Defective Interleukin-11 Receptor Maturation and Drive Craniosynostosis-like Disease in Mice. Cell Rep 25(1): 10-18.e5 |
| 64. | Garbers C, Heink S, Korn T, Rose-John S (2018) Interleukin-6: Designing specific therapeutics for a complex cytokine. Nat Rev Drug Discov 17(6): 395-412 |
| 63. | Wunderlich CM, Ackermann JP, Ostermann AL, Adams-Quack P, Vogt MC, Tran ML, Nikolajev A, Waisman A, Garbers C, Theurich S, Mauer J, Hövelmann N, Wunderlich FT (2018) Obesity exacerbates colitis-associated cancer via IL-6-regulated macrophage polarisation and CCL-20/CCR-6-mediated lymphocyte recruitment. Nat Commun 9(1): 1646 |
| 62. | Lokau J, Garbers C (2018) The length of the Interleukin-11 receptor stalk determines its capacity for classic signaling. J Biol Chem 293(17): 6398-6409 |
| 61. | Schmidt S, Schumacher N, Schwarz J, Tangermann S, Kenner L, Schlederer M, Sibilia M, Linder M, Altendorf-Hofmann A, Knösel T, Gruber ES, Oberhuber G, Bolik J, Rehman A, Sinha A, Lokau J, Arnold P, Cabron AS, Zunke F, Becker-Pauly C, Preaudet A, Nguyen P, Huynh J, Afshar-Sterle S, Chand AL, Westermann J, Dempsey PJ, Garbers C, Schmidt-Arras D, Rosenstiel P, Putoczki T, Ernst M, Rose-John S (2018) ADAM17 is required for EGF-R-induced intestinal tumors via IL-6 trans-signaling. J Exp Med 215(4): 1205-1225 |
| 60. | Agthe M, Garbers Y, Grötzinger J, Garbers C (2018) Two N-Linked Glycans Differentially Control Maturation, Trafficking and Proteolysis, but not Activity of the IL-11 Receptor. Cell Physiol Biochem 45(5): 2071-2085 |
| 59. | Garbers C, Rose-John S (2018) Dissecting Interleukin-6 Classic- and Trans-Signaling in Inflammation and Cancer. Methods Mol Biol 1725: 127-140 |
2017
| 58. | Lokau J, Göttert S, Arnold P, Düsterhöft S, Massa López D, Grötzinger J, Garbers C (2017) The SNP rs4252548 (R112H) which is associated with reduced human height compromises the stability of IL-11. Biochim Biophys Acta 1865(3): 496-506 |
| 57. | Moll JM, Wehmöller M, Frank NC, Homey L, Baran P, Garbers C, Lamertz L, Axelrod JH, Galun E, Mootz HD, Scheller J (2017) Split2 Protein-Ligation Generates Active IL-6-Type Hyper-Cytokines from Inactive Precursors. ACS Synth Biol 6(12): 2260-2272 |
| 56. | Dixit A, Bottek J, Beerlage AL, Schuettpelz J, Thiebes S, Brenzel A, Garbers C, Rose-John S, Mittrücker HW, Squire A, Engel DR (2017) Frontline Science: Proliferation of Ly6C+ monocytes during urinary tract infections is regulated by IL-6 trans-signaling. J Leukoc Biol pii: jlb.3HI0517-198R |
| 55. | Agthe M, Garbers Y, Putoczki T, Garbers C (2017) Interleukin-11 classic but not trans-signaling is essential for fertility in mice. Placenta 57: 13-16 |
| 54. | Lokau J, Flynn CM, Garbers C (2017) Cleavage of the Interleukin-11 receptor induces processing of its C-terminal fragments by the gamma-secretase and the proteasome. Biochem Biophys Res Commun 16;491(2): 296-302 |
| 53. | Lokau J, Agthe M, Flynn CM, Garbers C (2017) Proteolytic control of Interleukin-11 and Interleukin-6 biology. Biochim Biophys Acta 1864(11 Pt B): 2105-2117 |
| 52. | Arnold P, Boll I, Rothaug M, Schumacher N, Schmidt F, Wichert R, Schneppenheim J, Lokau J, Pickhinke U, Koudelka T, Tholey A, Rabe B, Scheller J, Lucius R, Garbers C, Rose-John S, Becker-Pauly C (2017) Meprin Metalloproteases Generate Biologically Active Soluble Interleukin-6 Receptor to Induce Trans-Signaling. Sci Rep 7:44053 |
| 51. | Garbers C, Rose-John S (2017) The Balance between Treg and TH17 cells: CD11b and Interleukin-6. Eur J Immunol 47(4):629-632 |
| 50. | Tode J, Richert E, Koinzer S, Klettner A, Pickhinke U, Garbers C, Rose-John S, Nölle B, Roider J (2017) Intravitreal injection of anti-Interleukin (IL)-6 antibody attenuates experimental autoimmune uveitis in mice. Cytokine 96: 8-15 |
| 49. | Balic JJ, Garbers C, Rose-John S, Yu L, Jenkins BJ (2017) Interleukin-11-driven gastric tumourigenesis is independent of trans-signalling. Cytokine 92:118-123 |
| 48. | Aparicio-Siegmund S, Deseke M, Lickert A, Garbers C (2017) Trans-signaling of interleukin-6 (IL-6) is mediated by the soluble IL-6 receptor, but not by soluble CD5. Biochem Biophys Res Comm 484(4):808-812 |
| 47. | Lokau J, Wandel M, Garbers C (2017) Enhancing Interleukin-6 and Interleukin-11 Receptor Cleavage. Int J Biochem Cell Biol 85:6-14 |
| 46. | Riethmueller S, Somasundaram P, Ehlers JC, Hung CW, Flynn CM, Lokau J, Agthe M, Düsterhöft S, Zhu Y, Grötzinger J, Lorenzen I, Koudelka T, Yamamoto K, Pickhinke U, Wichert R, Becker-Pauly C, Rädisch M, Albrecht A, Hessefort M, Stahnke D, Unverzagt C, Rose-John S, Tholey A, Garbers C (2017) Proteolytic Origin of the Soluble Human IL-6R In Vivo and a Decisive Role of N-Glycosylation. PLoS Biol 15(1): e2000080 |
| 45. | Wittlich M, Dudek M, Böttcher JP, Schanz O, Hegenbarth S, Bopp T, Schmitt E, Kurts C, Garbers C, Rose John S, Knolle PA, Wohlleber D (2017) Liver sinusoidal endothelial cell cross-priming is supported by CD4 T cell-derived IL-2. J Hepatol 66(5):978-986 |
| 44. | Heink S, Yogev N, Garbers C, Herwerth M, Aly L, Gasperi C, Husterer V, Croxford AL, Möller-Hackbarth K, Bartsch HS, Sotlar K, Krebs S, Regen T, Blum H, Hemmer B, Misgeld T, Wunderlich TF, Hidalgo J, Oukka M, Rose-John S, Schmidt-Supprian M, Waisman A, Korn T (2017) Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells. Nat Immunol 18(1): 74-85 |
2016
| 43. | Lorenzen I, Lokau J, Korpys Y, Oldefest M, Flynn CM, Künzel U, Garbers C, Freeman M, Grötzinger J, Düsterhöft S (2016) Control of ADAM17 activity by regulation of its cellular localisation. Sci Rep 6: 35067 |
| 42. | Schumacher N, Schmidt S, Schwarz J, Dohr D, Lokau J, Scheller J, Garbers C, Chalaris A, Rose-John S, Rabe B (2016) Circulating Soluble IL-6R but Not ADAM17 Activation Drives Mononuclear Cell Migration in Tissue Inflammation. J Immunol 197(9): 3705-3715 |
| 41. | Ruwanpura SM, McLeod L, Dousha LF, Seow HJ, Alhayyani S, Tate MD, Deswaerte V, Brooks GD, Bozinovski S, McDonald M, Garbers C, King PT, Bardin PG, Vlahos R, Rose-John S, Anderson GP, Jenkins BJ (2016) Therapeutic targeting of the IL-6 trans-signalling/mTORC1 axis in pulmonary emphysema. Am J Respir Crit Care Med 194(12): 1494-1505 |
| 40. | Monhasery N, Moll J, Cuman C, Franke M, Lamertz L, Nitz R, Görg B, Häussinger D, Lokau J, Floss DM, Piekorz R, Dimitriadis E, Garbers C, Scheller J (2016) Transcytosis of IL-11 and Apical Redirection of gp130 Is Mediated by IL-11α Receptor. Cell Rep 16(4): 1067-81 |
| 39. | Lokau J, Agthe M, Garbers C (2016) Generation of Soluble Interleukin-11 and Interleukin-6 Receptors: A Crucial Function for Proteases during Inflammation. Mediat Inflamm 2016: 1785021 |
| 38. | Wolf J, Waetzig GH, Chalaris A, Reinheimer TM, Wege H, Rose-John S, Garbers C (2016) Different Soluble Forms of the Interleukin-6 Family Signal Transducer gp130 Fine-Tune the Blockade of Interleukin-6 Trans-Signaling. J Biol Chem 291(31): 16186-96 |
| 37. | Riethmueller S, Ehlers JC, Lokau J, Düsterhöft S, Knittler K, Dombrowsky G, Grötzinger J, Rabe B, Rose-John S, Garbers C (2016) Cleavage Site Localization Differentially Controls Interleukin-6 Receptor Proteolysis by ADAM10 and ADAM17. Sci Rep 6: 25550 |
| 36. | Franke M, Schröder J, Monhasery N, Ackfeld T, Hummel TM, Rabe B, Garbers C, Becker-Pauly C, Flos DM, Scheller J (2016) Human and murine Interleukin 23 receptors are novel substrates for a disintegrin and metalloproteases ADAM10 and ADAM17. J Biol Chem 13;291(20): 10551-61 |
| 35. | Lokau J, Garbers C (2016) Signal transduction of Interleukin-11 and Interleukin-6 α-Receptors. Receptors Clin Investig 3: e1190. doi: 10.14800/rci.1190 |
| 34. | Lokau J, Nitz R, Agthe M, Monhasery N, Aparicio-Siegmund S, Schumacher N, Wolf J, Möller-Hackbarth K, Waetzig GH, Grötzinger J, Müller-Newen G, Rose-John S, Scheller J, Garbers C (2016) Proteolytic cleavage governs Interleukin-11 trans-signaling. Cell Rep 14(7): 1761-73 |
| 33. | Wolf J, Waetzig GH, Reinheimer TM, Scheller J, Rose-John S, Garbers C (2016) A soluble form of the interleukin-6 family signal transducer gp130 is dimerized via a C-terminal disulfide bridge resulting from alternative mRNA splicing. Biochem Biophys Res Commun 470(4): 870-6 |
2015
| 32. | Nitz R, Lokau J, Aparicio-Siegmund S, Scheller J, Garbers C (2015) Modular organization of Interleukin-6 and Interleukin-11 α-receptors. Biochimie 119: 175-82 |
| 31. | Schumacher N, Meyer D, Mauermann A, von der Heyde J, Wolf J, Schwarz J, Knittler K, Murphy G, Michalek M, Garbers C, Bartsch JW, Guo S, Schacher B, Eickholz P, Chalaris A, Rose-John S, Rabe B (2015) Shedding of Endogenous Interleukin-6 Receptor (IL-6R) Is Governed by A Disintegrin and Metalloproteinase (ADAM) Proteases while a Full-length IL-6R Isoform Localizes to Circulating Microvesicles. J Biol Chem 290(43): 26059-71 |
| 30. | Aparicio-Siegmund S, Garbers C (2015) The biology of Interleukin-27 reveals unique pro- and anti-inflammatory functions in immunity. Cytokine Growth Factor Rev 26(5): 579-86 |
| 29. | Garbers C, Aparicio-Siegmund S, Rose-John S (2015) The IL-6/gp130/STAT3 signaling axis: Recent advances towards specific inhibition. Curr Opin Immunol Jun 34: 75-82 |
| 28. | Rudolph N, Meyer T, Franzen K, Garbers C, Schaper F, Streif S, Dittrich A, Findeisen R (2015) A two-level approach for fusing early signaling events and long term biological responses. IFAC-PapersOnLine 48(8): 1228-1233 |
| 27. | Garbers C, Rose-John S (2015) Pharmaceutical Relevant Cytokine Receptors: Lessons from the First Drafts of the Human Proteome. J Proteome Res Feb 6;14(2): 1330-2 |
2014
| 26. | Aparicio-Siegmund S, Moll JM, Lokau J, Grusdat M, Schröder J, Plöhn S, Rose-John S, Grötzinger J, Lang PA, Scheller J, Garbers C (2014) Recombinant p35 from Bacteria Can Form Interleukin (IL-)12, but Not IL-35. PLoS One 26;9(9): e107990 |
| 25. | Müller J, Gorressen S, Grandoch M, Feldmann K, Kretschmer I, Lehr S, Ding Z, Schmitt JP, Schrader J, Garbers C, Heusch G, Kelm M, Scheller J, Fischer JW (2014) Interleukin-6-dependent phenotypic modulation of cardiac fibroblasts after acute myocardial infarction. Basic Res Cardiol 109, 440 |
| 24. | Böttcher JP, Schanz O, Garbers C, Zaremba A, Hegenbarth S, Kurts C, Beyer M, Schultze JL, Kastenmüller W, Rose-John S, Knolle PA (2014) IL-6 trans-Signaling-Dependent Rapid Development of Cytotoxic CD8(+) T Cell Function. Cell Rep 8, 1318-1327 |
| 23. | Effenberger T, von der Heyde J, Bartsch K, Garbers C, Schulze-Osthoff K, Chalaris A, Murphy G, Rose-John S, Rabe B (2014) Senescence-associated release of transmembrane proteins involves proteolytic processing by ADAM17 and microvesicle shedding. FASEB J 28(11):4847-56 |
| 22. | Wolf J, Rose-John S, Garbers C (2014) Interleukin-6 and its receptors: A highly regulated and dynamic system. Cytokine 70(1):11-20 |
| 21. | Sommer J, Garbers C, Wolf J, Trad A, Moll JM, Sack M, Fischer R, Grötzinger J, Waetzig GH, Floss DM, Scheller J (2014) Alternative intronic polyadenylation generates the interleukin-6 trans-signaling inhibitor SGP130-E10. J Biol Chem 289(32):22140-50 |
| 20. | Garbers C, Monhasery N, Aparicio-Siegmund S, Lokau J, Baran P, Nowell MA, Jones SA, Rose-John S, Scheller J (2014) The Interleukin-6 Receptor Asp358Ala Single Nucleotide Polymorphism rs2228145 Confers Increased Proteolytic Conversion Rates by ADAM Proteases. Biochim Biophys Acta 1842, 1485-1494 |
| 19. | Sommer J, Engelowski E, Baran P, Garbers C, Floss D, Scheller J (2014) Interleukin-6, but not the interleukin-6 receptor plays a role in recovery from dextran sodium sulfate-induced colitis. Int J Mol Med 34, 651-60 |
| 18. | Wagener EM, Aurich M, Aparicio-Siegmund S, Floss D, Garbers C, Breusing K, Rabe B, Schwanbeck R, Grötzinger J, Rose-John S, Scheller J (2014) The amino acid exchange R28E in ciliary neurotrophic factor (CNTF) abrogates IL-6R- but retains CNTFR-dependent signaling via gp130/LIFR. J Biol Chem 289, 18442-18450 |
| 17. | Düsterhöft S, Höbel K, Oldefest M, Lokau J, Waetzig GH, Chalaris A, Garbers C, Scheller J, Rose-John S, Lorenzen I, Grötzinger J (2014) “A Disintegrin And Metalloprotease-17 Dynamic Interaction Sequence” (CANDIS) – the sweet tooth for the human interleukin-6 receptor. J Biol Chem 289, 16336-16348 |
| 16. | Aparicio-Siegmund S, Sommer J, Monhasery N, Schwanbeck R, Keil E, Pfeffer K, Rose-John S, Scheller J, Garbers C (2014) Inhibition of protein kinase II (CKII) prevents induced signal transducer and activator of transcription (STAT) 1/3 and constitutive STAT3 activation. Oncotarget 5, 2131-2148 |
| 15. | Scheller J, Garbers C, Rose-John S (2014) Interleukin-6: From basic biology to selective blockade of pro-inflammatory activities. Semin Immunol 26, 2-12 |
| 14. | Schweigert O, Dewitz C, Möller-Hackbarth K, Trad A, Garbers C, Rose-John S, Scheller J (2014) Soluble T cell immunoglobulin and mucin domain (TIM-) 1 and 4 generated by A Disintegrin And Metalloproteases (ADAM-)10 and 17 bind to phosphatidylserine. Biochim Biophys Acta 1843, 275-287 |
2013
| 13. | Möller-Hackbarth K, Dewitz C, Schweigert O, Trad A, Garbers C, Rose-John S, Scheller J (2013) ADAM10 AND ADAM17 are major sheddases of T cell immunoglobulin and mucin domain 3 (TIM-3). J Biol Chem 288, 34529-34544 |
| 12. | Garbers C, Kuck F, Aparicio-Siegmund S, Konzak K, Kessenbrock M, Sommerfeld A, Häussinger D, Lang PA, Brenner D, Mak TW, Rose-John S, Essmann F, Schulze-Osthoff K, Piekorz RP, Scheller J (2013) Cellular senescence or EGFR signaling induces Interleukin 6 (IL-6) receptor expression controlled by mammalian target of rapamycin (mTOR). Cell Cycle 12, 3421-3432 |
| 11. | Garbers C, Scheller J (2013) Interleukin-6 and interleukin-11: same same but different. Biol Chem 394, 1145-1161 |
| 10. | Baran P, Nitz R, Grötzinger J, Scheller J, Garbers C (2013) Minimal interleukin (IL-)6 receptor stalk composition for IL-6R shedding and IL-6 classic signaling. J Biol Chem 288, 14756-14768 |
| 9. | Garbers C, Spudy B, Aparicio-Siegmund S, Waetzig GH, Sommer J, Hölscher C, Rose-John S, Grötzinger J, Lorenzen I, Scheller J (2013) An Interleukin-6 Receptor-dependent Molecular Switch Mediates Signal Transduction of the IL-27 Cytokine Subunit p28 (IL-30) via a gp130 Protein Receptor Homodimer. J Biol Chem 288, 4346-4354 |
2012
| 8. | Garbers C, Hermanns H, Schaper F, Müller-Newen G, Grötzinger J, Rose-John S, Scheller J (2012) Plasticity and cross-talk of Interleukin 6-type cytokines. Cytokine Growth Factor Rev 23, 85-182 |
| 7. | Lorenzen I, Lokau J, Düsterhoft S, Trad A, Garbers C, Scheller J, Rose-John S, Grötzinger J (2012) The membrane-proximal domain of A Disintegrin and Metalloprotease 17 (ADAM17) is responsible for recognition of the interleukin-6 receptor and interleukin-1 receptor II. FEBS Lett 586, 1093-1100 |
| 6. | Sommer J, Effenberger T, Volpi E, Waetzig G, Bernhardt M, Suthaus J, Garbers C, Rose-John S, Flos D, Scheller J (2012) Constitutively active mutant gp130 receptor protein from inflammatory hepatocellular adenoma is inhibited by an anti-gp130 antibody that specifically neutralizes interleukin 11 signaling. J Biol Chem 287, 13743-13751 |
2011
| 5. | Garbers C, Thaiss W, Jones GW, Waetzig GH, Lorenzen I, Guilhot F, Lissilaa R, Ferlin WG, Grötzinger J, Jones SA, Rose-John S, Scheller J (2011) Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor. J Biol Chem 286, 42959-42970 |
| 4. | Scheller J, Chalaris A, Garbers C, Rose-John S (2011) ADAM17: a molecular switch to control inflammation and tissue regeneration. Trends Immunol 32, 380-387 |
| 3. | Garbers C, Jänner N, Chalaris A, Moss ML, Flos M, Meyer D, Koch-Nolte F, Rose-John S, Scheller J (2011) Species specificity of ADAM10 and ADAM17 proteins in interleukin-6 (IL-6) trans-signaling and novel role of ADAM10 in inducible IL-6 receptor shedding. J Biol Chem 286, 14804-14811 |
| 2. | Chalaris A, Garbers C, Rabe B, Rose-John S, Scheller J (2011) The soluble Interleukin 6 receptor: generation and role in inflammation and cancer. Eur J Cell Biol 90, 484-494 |
| 1. | Malchow S, Thaiss W, Jänner N, Waetzig GH, Gewiese-Rabsch J, Garbers C, Yamamoto K, Rose-John S, Scheller J (2011) Essential role of neutrophil mobilization in concanavalin A-induced hepatitis is based on classic IL-6 signaling but not on IL-6 trans-signaling. Biochim Biophys Acta 1812, 290-301 |
